
Isoverticine
CAS No. 23496-43-7
Isoverticine( —— )
Catalog No. M29173 CAS No. 23496-43-7
Isoverticine exhibits significant antitussive, expectorant and anti-inflammatory activities, it also displays significant cytotoxicity.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 236 | Get Quote |
![]() ![]() |
100MG | Get Quote | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameIsoverticine
-
NoteResearch use only, not for human use.
-
Brief DescriptionIsoverticine exhibits significant antitussive, expectorant and anti-inflammatory activities, it also displays significant cytotoxicity.
-
DescriptionIsoverticine exhibits significant antitussive, expectorant and anti-inflammatory activities, it also displays significant cytotoxicity.(In Vitro):Isoverticine had significant cytotoxic activity, with IC50s of 49.56, 31.63, 61.91 and 108.8 μg/mL, respectively.
-
In VitroIsoverticine displays cytotoxicity, with IC50s of 49.56, 31.63, 61.91 and 108.8 μg/mL, respectively.
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetBcl-2
-
RecptorBCL
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number23496-43-7
-
Formula Weight431.661
-
Molecular FormulaC27H45NO3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (231.67 mM)
-
SMILES[H][C@@]12CC[C@@]3([H])[C@@]([H])(CN4C[C@@H](C)CC[C@@]4([H])[C@@]3(C)O)[C@]1([H])C[C@@]1([H])[C@@]2([H])C[C@@H](O)[C@@]2([H])C[C@@H](O)CC[C@]12C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog



related products
-
Navitoclax-piperazin...
Navitoclax-piperazine is an inhibitor of B-cell lymphoma extra large (BCL-XL).
-
DAN 004
A small molecule Bax inhibitor that inhibits Bax/Bak oligomerization and prevents mitochondrial outer membrane permeabilization (MOMP) with IC50 of 0.7 uM.
-
BM-957
BM-957 is a highly potent, dual Bcl-2 and Bcl-xL inhibitor with Ki of <1 nM for both, IC50 of 5.4 and 6.0 nM, respectively.